Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series

Xenofon Baraliakos; Styliani Tsiami; Sooraj Vijayan; Haewon Jung; Nick Barkham

doi:10.1002/ccr3.5205

Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series

Clin Case Rep. 2022 Jan 20;10(1):e05205. doi: 10.1002/ccr3.5205. eCollection 2022 Jan.

Authors

Xenofon Baraliakos¹, Styliani Tsiami¹, Sooraj Vijayan^{2

3}, Haewon Jung⁴, Nick Barkham²

Affiliations

¹ Ruhr-Universität Bochum Rheumazentrum Ruhrgebiet Herne Germany.
² Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust Wolverhampton UK.
³ SUT Academy of Medical Sciences Thiruvananthapuram India.
⁴ Celltrion Healthcare Co., Ltd Incheon Korea.

Abstract

The COVID-19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT-P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT-P13 SC suggest that patients receiving IV infliximab should be offered a switch to CT-P13 SC.

Keywords: COVID‐19; CT‐P13 SC; infliximab SC; infliximab subcutaneous; psoriatic arthritis; real‐world evidence.

Publication types

Case Reports